Home › Steatotic Liver Disease › New York › New York City
Steatotic Liver Disease clinical trials in New York City, NY
16 studies for Steatotic Liver Disease are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
- 89bio Clinical Study Site, New York
- 89bio Clinical Study Site, New York
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
- 89bio Clinical Study Site, New York
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 3
- GSK Investigational Site, New York
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RecruitingPhase 2
- New York Presbyterian/Weill Cornell, New York
- Columbia University Iriving School of Medicine, New York
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
RecruitingPhase 2
- Columbia University Irving Medical Center, New York
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
RecruitingPhase 3
- NYU Langone Health, New York
- IMA Clinical Research Manhattan, New York
- New York Gastroenterology Associates, New York
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RecruitingPhase 3
- Akero Clinical Study Site, New York
- Akero Clinical Study Site, New York
- Akero Clinical Study Site, New York
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RecruitingPhase 3
- GSK Investigational Site, New York
Human Models of Selective Insulin Resistance: Alpelisib, Part I
RecruitingPhase 1Healthy volunteers welcome
- Columbia University Irving Medical Center, New York
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
RecruitingPhase 2
- GSK Investigational Site, New York
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RecruitingPhase 3
- GSK Investigational Site, New York
- GSK Investigational Site, New York
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
RecruitingPhase 2
- GSK Investigational Site, New York
Effect of Insulin Lowering on Lipogenesis
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Recruiting
- Icahn School of Medicine at Mount Sinai, New York
Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
RecruitingHealthy volunteers welcome
- Weill Cornell Medicine, New York
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RecruitingHealthy volunteers welcome
- Mount Sinai Morningside, New York
About Steatotic Liver Disease
Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.
More about Steatotic Liver Disease on MedlinePlus
Steatotic Liver Disease trials in other cities
- San Antonio, TX17 studies
- Miami, FL16 studies
- San Diego, CA14 studies
- Houston, TX13 studies
- Austin, TX13 studies
- Richmond, VA12 studies
- Tucson, AZ10 studies
- Chandler, AZ10 studies
- St. Louis, MO9 studies
- Dallas, TX9 studies
- Hialeah, FL9 studies
- Orlando, FL9 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.